SynthesisReviews in medical virology2021
C-reactive protein as an effector molecule in Covid-19 pathogenesis.
Synthesis in Reviews in medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- The impact of the COVID-19 pandemic on osteoporotic fractures: a systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials.Stem cell research & therapy · 2023Pooled it
- Prevalence of oral manifestations in COVID-19: A systematic review.Reviews in medical virology · 2022Pooled it
- C-reactive protein as an effector molecule in Covid-19 pathogenesis.Reviews in medical virology · 2021Pooled it
- Serum Apelin-13 and Galectin-3 in COVID-19: Associations With Routine Biochemical Parameters and Diagnostic Performance in a Case-Control Study.Journal of clinical laboratory analysis · 2026Article
- Early Cytokine Profiles in Critically Ill Patients with COVID-19 and Their Association with Mortality.Metabolites · 2026Article
- The prognostic value of red cell distribution width-to-albumin ratio (RAR) in COVID-19 pneumonia: implications for early diagnosis.Virology journal · 2026Article
- Serum proteomic profiling reveals potential predictive indicators for coronary artery calcification in stable ischemic heart disease.Journal of molecular histology · 2025Article
- Biomarkers associated with the diagnosis and prognosis ofFrontiers in cellular and infection microbiology · 2025Review
- Outcomes of COVID-19 in 24 hospitalized liver transplant recipients: an observational study.BMC infectious diseases · 2024Observational
- Fermented Rooibos tea (Aspalathus linearis) Ameliorates Sodium Fluoride-Induced Cardiorenal Toxicity, Oxidative Stress, and Inflammation via Modulation of NF-κB/IκB/IκKB Signaling Pathway in Wistar Rats.Cardiovascular toxicology · 2024Article
- Dynamic lymphocyte-CRP ratio as a predictor: a single-centre retrospective study on disease severity and progression in adult COVID-19 patients.The Journal of international medical research · 2024Article
- Gold single atom-based aptananozyme as an ultrasensitive and selective colorimetric probe for detection of thrombin and C-reactive protein.Mikrochimica acta · 2023Article
- Being Eaten Alive: How Energy-Deprived Cells Are Disposed of, Mediated by C-Reactive Protein-Including a Treatment Option.Biomedicines · 2023Article
- The Impact of Therapeutic Plasma Exchange on Inflammatory Markers and Acute Phase Reactants in Patients with Severe SARS-CoV-2 Infection.Medicina (Kaunas, Lithuania) · 2023Review
- COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters.International journal of molecular sciences · 2023Review
- Perspectives of (/memorandum for) systems thinking on COVID-19 pandemic and pathology.Journal of evaluation in clinical practice · 2023Article
- Developing Prediction Models for COVID-19 Outcomes: A Valuable Tool for Resource-Limited Hospitals.International journal of general medicine · 2023Article
- Clinical severity classes in COVID-19 pneumonia have distinct immunological profiles, facilitating risk stratification by machine learning.Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current pandemic caused by SARS-CoV-2 virus infection is known as Covid-19 (coronavirus disease 2019). This disease can be asymptomatic or can affect multiple organ systems. Damage induced by the virus is related to dysfunctional activity of the immune system, but the activity of molecules such as C-reactive protein (CRP) as a factor capable of inducing an inflammatory status that may be involved in the severe evolution of the disease, has not been extensively evaluated. A systematic review was performed using the NCBI-PubMed database to find articles related to Covid-19 immunity, inflammatory response, and CRP published from December 2019 to December 2020. High levels of CRP were found in patients with severe evolution of Covid-19 in which several organ systems were affected and in patients who died. CRP activates complement, induces the production of pro-inflammatory cytokines and induces apoptosis which, together with the inflammatory status during the disease, can lead to a severe outcome. Several drugs can decrease the level or block the effect of CRP and might be useful in the treatment of Covid-19. From this review it is reasonable to conclude that CRP is a factor that can contribute to severe evolution of Covid-19 and that the use of drugs able to lower CRP levels or block its activity should be evaluated in randomized controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.